Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ (5,422,000)	$ 1,682,000	$ (9,894,000)	$ 2,423,000	$ (3,740,000)	$ (7,471,000)	$ (6,000,000.0)
Adjustments to reconcile net loss to cash used in operating activities:
Change in fair value of common stock warrant liabilities	498,000		3,079,000		176,000	(5,082,000)
Gain on extinguishment of warrant liability						(47,000)
Change in fair value of contingent consideration					(140,000)
Issuance and offering costs					769,000
Depreciation					484,000	182,000
Amortization of intangible assets					48,000
Lease amortization					639,000	484,000
Loss on disposal of fixed assets					135,000
Net amortization of investment premium						(44,000)
Stock-based compensation	300,000		600,000		681,000	1,367,000
Realized gain on corporate securities					(10,222,000)
Write-down of fixed assets	210,000				210,000
Write-down of inventory and prepaid production costs					983,000	1,421,000
Changes in operating assets and liabilities:
Accounts receivable					259,000	199,000
Inventories					(633,000)	(8,031,000)
Prepaid expenses and other current assets					(938,000)	(1,276,000)
Other noncurrent assets					(153,000)	(15,000)
Accounts payable and accrued expenses					1,083,000	2,252,000
Amounts due to related parties					(47,000)	(18,000)
Unearned revenue					56,000	(42,000)
Other current liabilities					1,000
Other noncurrent liabilities					(1,000)	(43,000)
Operating lease payments					(590,000)	(384,000)
Net cash used in operating activities					(10,940,000)	(16,548,000)	(30,200,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment					(713,000)	(1,749,000)
Purchases of investments						(1,292,000)
Acquisitions, net of cash acquired					(4,250,000)
Proceeds from sales and maturities of investments					21,845,000	17,650,000
Net cash provided by investing activities					16,882,000	14,609,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from warrant exercises from June 2018 Offering						6,822,000
Proceeds from borrowings						3,108,000
Payment of transaction costs relating to extinguishment of warrant liability						(594,000)
Principal payments on debt					(2,019,000)	(15,000)
Proceeds from ESPP purchases					27,000	14,000
Capital contributions received from non-controlling interest					750,000	1,182,000
Net cash provided by financing activities					21,993,000	10,517,000
Effects of foreign currency translation on cash and cash equivalents					(1,000)
Net increase in cash, cash equivalents and restricted cash					27,934,000	8,578,000
Cash, cash equivalents and restricted cash — beginning of period		$ 16,043,000		$ 8,417,000	16,043,000	8,417,000	8,417,000
Cash, cash equivalents and restricted cash — end of period	$ 43,977,000		$ 16,995,000		43,977,000	16,995,000	$ 16,043,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes					1,000
Cash paid for interest					21,000	6,000
NONCASH INVESTING AND FINANCING ACTIVITIES:
Fixed assets acquired with notes payable						37,000
Shares of common stock issued at closing of Arcadia Wellness transaction					2,053,000
Right of use assets obtained in exchange for new operating lease liabilities					913,000	3,947,000
Purchases of fixed assets included in accounts payable and accrued expenses					58,000
January 2021 PIPE Purchase Agreement [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants from January 2021 PIPE securities purchase agreement					25,147,000
Payments of offering costs relating to January 2021 PIPE securities purchase agreement					(1,912,000)
January 2021 Offering [Member]
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrants issued to placement agent and included in offering costs					$ 942,000
May 2020 Warrant Transaction [Member]
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrants issued to placement agent and included in offering costs						$ 215,000